BRAF and hematocrit: In our study, a total of four patients with HT experienced disease recurrence (N = 4/43, 9.3% of all patients with recurrence), with only a single patient (N = 1/43, 2.3% of all patients with recurrence) having HT and a BRAF-wild type carcinoma.